Abstract
Abstract: The use of mRNA in therapeutics has lately emerged as a powerful strategy for alleviating the various viral infections and diseased conditions, along with prophylaxis. However, a key challenge in their efficient delivery is the protection of the nucleic acid from degradation followed by mRNA transport to the cells. In this regard, clinical translation of mRNA therapeutics has largely been facilitated with the advent of lipid-based nanoparticles (LBNPs). LBNPs–mRNA vaccines currently being employed for Covid 19 is one such instance substantiating and endorsing the use of lipidic nanocarriers for mRNA therapeutics. Thus, the current review article aims to furnish information on developmental challenges, different aspects of lipid-based carrier systems for mRNA delivery, their vital applications in different diseases and the future potential of LBNPs in therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
